News & Events


HIVINNOV (Grant n°305137) is a collaborative research project supported by the European Union

HIVinnov co-organisor of a satellite symposium at the EACS AIDS conference

HIVinnov will co-organise a satelite symposium at the 15th EACS (European AIDS Clinical Society) European AIDS conference in Barcelona on October 20th 2015.

HIV reactivation from latency occurs 1 week after stopping antiretrovirals

This study published by Prof. Miles Davenport from the university of New Wales (Australia) in PLOS Pathogens provides new insights on the frequency of activation among latently infected cells

Why do experimental HIV vaccines backfire?


Several HIV vaccine candidates have shown the opposite effect of the protective one that was intended. New works by Guido Silvestri et al in the Proceedings of the National Academy of Sciences suggests an explanation.


To read the abstract on PubMed

To read the Medical News Today article


Identification of the AIDS epidemic's origin


*After the publication of his 2011 book, "The origin of AIDS", Professor Jacques Pepin released a publication in Science detailling the ealry spread and epidemic ignition of HIV-1.


October 20014 newsletter


You can download the October 2014 HIVinonv newsletter by Clicking here


HSP 90: a chaperone for HIV-1


Dr. Ariberto Fassati's team (MRC) with Dr. Jun Siong Low's team (UCL) have published a new article in Parasitology (Cambridge Journals). The article can be found on Pubmed with the PMID : 25004926



Heat shock protein 90 controls HIV-1 reactivation from latency


Dr. Ariberto Fassati's team has published a new article in the Proceedings of the National Academy of Sciences of the USA.


The publication can be fond on Pubmed under he following PMID : 24706778.



"Structural basis for nuclear import of splicing factors by human Transportin 3."

The Cancer Research UK (Dr. Peter Cherepanov) and the University College London (Dr. Ariberto Fassati), two partner teams in HIVinnov have published an article in the Proceedings of the National Academy of Sciences (PNAS). 


The Article has been published in PNAS under the PMID : 24449914


The publication is freely available on the PNAS website.



Dolutegavir approved in Europe

The European Commision has approved on January 21st the ViiV latest integrase inhibitor, Dolutegravir (marketed under the brand name Tivicay).


After Raltegravir (Isentress), Dolutegravir (Tivicay) is the second HIV integrase-inhibitor approved. 


To read the news report on "HIV & Hepatitis" click here.


To read the press release on Viiv Healthcare click here.